ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions
View by Date
Jump to:  View All • a b c d e f g h i j k l m n [o] p q r s t u v w x y z
  • Abstract Number: 1187
    Obesity Burden and Effects of Apremilast on Changes in Cardiometabolic Parameters by Obesity Status in Patients with Psoriasis (PsO) or Psoriatic Arthritis (PsA) in a Real-World Setting
  • Abstract Number: 0153
    Obesity Is Associated with Higher Odds of Malignancy Development Among Dermatomyositis Patients
  • Abstract Number: 2234
    Obesity, Adipokines, and Chronic and Persistent Pain in Rheumatoid Arthritis
  • Abstract Number: 0950
    Obstetric Outcomes in Women with Rheumatic Disease and COVID-19 in the Context of Vaccination Status: Data from the COVID-19 Global Rheumatology Alliance Registry
  • Abstract Number: 0677
    Obstructive Sleep Apnea in Primary Antiphospholipid Syndrome Impacts Damage Accrual
  • Abstract Number: 0601
    Occupational Inhaled Agents Constitute Major Risk Factors for Rheumatoid Arthritis, Particularly in the Context of Genetic Predisposition and Smoking
  • Abstract Number: 0673
    Occurrence and Severity of Bleeding in Adults with Immunogenic Thrombocytopenic Purpura with or Without Antiphospholipid Autoantibodies
  • Abstract Number: 0314
    Olokizumab Improved Patient Reported Outcomes in TNF Incomplete Responder (TNF-IR) Rheumatoid Arthritis Patients: Results from the Phase III Randomized Controlled Trial
  • Abstract Number: 0313
    Olokizumab Improves Patient Reported Outcomes in Moderate to Severely Active Rheumatoid Arthritis Patients Inadequately Controlled by Methotrexate (MTX-IR): Results from the Phase III Randomized Controlled Trial
  • Abstract Number: 0230
    Online Educational Module on Axial Spondyloarthritis Improves the Knowledge and Confidence of Non-rheumatology Providers
  • Abstract Number: 0215
    Online Teaching of Hand Examination Using Student-recorded Videos and Remotely Delivered Feedback: A Pilot Study
  • Abstract Number: 0435
    Onset of ANCA-associated Vasculitides in Systemic Sclerosis: Phenotype, Management and Outcomes
  • Abstract Number: 0073
    Opioid and Pain Medication Prescribing by Rheumatologists for Medicare Part D Beneficiaries from 2013 to 2019
  • Abstract Number: 0402
    Opioid Use and Healthcare Utilization in Adults with PsA and AS
  • Abstract Number: 0865
    Opioid Use in Youth with Inflammatory Bowel Disease (IBD)-related Arthritis
  • Abstract Number: 0822
    Optimal Use of Colchicine in COVID-19 Management from Rheumatologists’ Perspective: A Monocentric Observational Study During the SARS-CoV-2 Delta Variant Pandemic
  • Abstract Number: 0726
    Optimizing Laboratory Medication Safety Monitoring in Patients with JIA to Advance Value-based Care
  • Abstract Number: 0006
    Oral Administration of a Novel Pyrrolopyrimidine Derivative That Inhibits BAFF Signaling Suppresses B Cell Differentiation and Production of Autoantibody in Autoimmune Model Mice
  • Abstract Number: 1689
    Oral Ginger Supplementation Counteracts NETosis in Autoimmune Mouse Models and in Healthy Humans
  • Abstract Number: 0325
    Ordering Practices and Diagnostic Utility of Cardiac MRI in SLE Patients at a Single Academic Institution
  • Abstract Number: 1891
    Osteoarthritis of the Knee, Inflammation, and the Effect of Adalimumab: A Randomized Placebo-Controlled Trial
  • Abstract Number: 1661
    Osteoclastogenesis and Vascular Endothelial Growth Factor Blood Levels in Patients with Systemic Sclerosis with and Without Calcinosis Cutis
  • Abstract Number: 0574
    Osteoporosis in Elderly Men; An Underestimated and Underdiagnosed Morbid Entity
  • Abstract Number: 0437
    Outcome Measures in Patients with Neurologic Involvement in ANCA-associated Vasculitis: Data from Multicenter Longitudinal Observational Study
  • Abstract Number: 1872
    Outcome of Idiopathic Inflammatory Myositis Patients Who Received Rituximab: A Single Centre Retrospective Study
  • Abstract Number: 2022
    Outcome of Pregnancy in Women with Primary Sjögren’s Syndrome Compared to the General Population: The French Multicenter Prospective GR2 Study
  • Abstract Number: 0854
    Outcome of Uveitis in Juvenile Idiopathic Arthritis and Spondyloarthritis Patients – a 5-year Follow up Study
  • Abstract Number: 1566
    Outcome of Vascular Involvement of Behçet Syndrome Treated with Infliximab: A Retrospective Cohort Study
  • Abstract Number: 1929
    Outcomes and Safety of Anakinra for the Treatment of Multisystem Inflammatory Syndrome in Children
  • Abstract Number: 1420
    Outcomes in Patients with Rheumatoid Arthritis Initiating Monotherapy with Etanercept, Adalimumab, or Janus Kinase Inhibitors
  • Abstract Number: 0679
    Outcomes of Antiphospholipid Antibody Syndrome and Acute Coronary Syndrome: Analysis of National Inpatient Sample 
  • Abstract Number: 2101
    Outcomes of Autoimmune Hemolytic Anemia in Patients with Systemic Lupus Erythematosus: A Nationwide Inpatient Sample Study
  • Abstract Number: 0866
    Outcomes of Children with Uveitis Associated with Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy (ADNIV) Treated with Methotrexate and Infliximab
  • Abstract Number: 1588
    Outcomes of Etanercept and Janus Kinase Inhibitor Treatment After First-line Use of Adalimumab in Patients with Rheumatoid Arthritis
  • Abstract Number: 1082
    Outcomes of Methotrexate as an Initial Induction and Maintenance Regimen for Localized Granulomatosis with Polyangiitis: A Retrospective Review
  • Abstract Number: 0850
    Outcomes of Patients with Juvenile Idiopathic Arthritis Following Failure of Initial Tumor Necrosis Factor Inhibitor Medication in the Childhood Arthritis and Rheumatology Research Alliance Registry
  • Abstract Number: 1976
    Outcomes of the First Episode of STEMI in Rheumatoid Arthritis from the National Inpatient Sample Database 2016-2019
  • Abstract Number: 2057
    Outpatient Visit Adherence and Impact on Disease-related Morbidity in Childhood-onset Systemic Lupus Erythematosus (cSLE)
  • Abstract Number: 1591
    Overall and Post-vaccination Prevalence of Severe COVID-19-related Events Among Commercially Insured Patients with Systemic Lupus Erythematosus and the General U.S. Population
Jump to:  View All • a b c d e f g h i j k l m n [o] p q r s t u v w x y z
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology